Caspofungin Use in Daily Clinical Practice for Treatment of Invasive Aspergillosis: Results of a Prospective Observational Registry by Maertens, Johan et al.
RESEARCH ARTICLE Open Access
Caspofungin Use in Daily Clinical Practice for
Treatment of Invasive Aspergillosis: Results
of a Prospective Observational Registry
Johan Maertens
1†, Gerlinde Egerer
2†, Wan Shik Shin
3†, Dietmar Reichert
4†, Michael Stek
5†, Sheenu Chandwani
6†,
Malathi Shivaprakash
7*†, Claudio Viscoli
8†, the study team CAN-DO(IA)
Abstract
Background: A prospective observational registry assessed real world experience with caspofungin monotherapy
or combination therapy for the initial or salvage treatment of proven or probable invasive aspergillosis (IA).
Methods: Data were collected from April 2006 to September 2007 for patients treated with caspofungin for a
single episode of IA. Clinical effectiveness was categorized as favorable (complete or partial) or unfavorable (stable
disease or failure) at the end of caspofungin therapy (EOCT).
Results: Consecutive patients (n = 103) with proven or probable IA (per EORTC/MSG criteria) were identified from
11 countries. Malignancy (76.7%), neutropenia (64.1%), allogeneic hematopoietic stem cell transplantation (HSCT,
22.3%), solid organ transplantation (8.7%), autologous HSCT (4.9%), and HIV/AIDS (2.9%) were the most common
underlying conditions. Most patients (84.5%) had pulmonary IA. Aspergillus fumigatus was the most frequently
isolated species. The majority of patients received caspofungin monotherapy (82.5%) primarily as salvage therapy
(82.4%). The main reason for switching to salvage therapy was clinical failure of the first-line therapy (69%). A
favorable response at EOCT was seen in 56.4% (57/101) of patients overall, including 56.5% (48/85) and 56.3% (9/
16) of patients receiving caspofungin monotherapy and combination therapy, respectively. Favorable response
rates in clinically relevant subgroups were: malignancy, 51.9% (41/79); allogeneic HSCT, 56.5% (13/23); and
neutropenia at time of hospitalization, 53.0% (35/66). There was a 72.3% (73/101) survival at 7 days after EOCT.
Serious adverse events related to caspofungin were reported in 4 cases (3.9%); 3 patients (2.9%) discontinued
treatment due to an adverse event related to caspofungin.
Conclusions: Caspofungin was both effective and well tolerated among high-risk patient groups such as those
with neutropenia and active malignancies.
Background
Invasive aspergillosis (IA) accounts for approximately
30% of all invasive fungal infections [1]. In spite of
recent improvements in our ability to diagnose the dis-
ease at an earlier stage and the availability of new anti-
fungal drugs, IA still carries a high mortality rate [2,3].
In addition, in carefully selected study patients with pro-
ven, probable or possible IA, overall response rates are
approximately 50% for both voriconazole (52.8%), a cur-
rent drug of choice, and for liposomal amphotericin B
(46-50%), the currently recommended alternative for
first-line therapy [1,4,5]. Response rates are considerably
lower among allogeneic hematopoietic stem cell trans-
plant recipients (HSCT) than in patients with active
hematologic malignancies [4,5].
Caspofungin is the first echinocandin approved for use
in the treatment of IA in patients who are refractory to
or intolerant of other agents. In this setting, caspofungin
monotherapy has an overall success rate of 45% to 60%
in the context of clinical trials and outside clinical trials
in an open case setting [6-9]. However, there is a need
for continuing studies of caspofungin efficacy and toler-
ability because the efficacy of these agents may change
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practices compared with clinical trials. This article
describes a prospective observational registry developed
to assess daily clinical practice with caspofungin when
used as monotherapy or in combination therapy for
initial or salvage treatment of proven or probable IA.
Methods
A prospective observational registry was developed to
collect data from consecutive patients treated with cas-
pofungin monotherapy or caspofungin combination
therapy for proven or probable IA. The protocol was
approved by the institutional review boards at each par-
ticipating center. Data collection was conducted in
accordance with the ethical standards outlined in the
declaration Helsinki and guidelines for good clinical
practices [10].
Patient Population
Only patients older than 16 years of age who were
receiving caspofungin for treatment of proven or prob-
able IA and who were not currently participating in
another Merck sponsored clinical trial for invasive fun-
gal infections were eligible. Investigators identified eligi-
ble patients based on their diagnosis of aspergillus
infection and categorized their infection based on their
clinical judgment and local practice standards. The
sponsors of the study provided guidance to investigators
f o rp r o v e no rp r o b a b l eAspergillus infection diagnosis
according to the 2002 European Organisation for
Research and Treatment of Cancer/Mycoses Study
Group (EORTC/MSG) criteria [11]. Patients with radi-
ologic signs highly suggestive of aspergillosis were eligi-
ble for inclusion. There were no protocol-defined
exclusion criteria.
Registry Design
Given the observational nature of this study, no investi-
gational or approved medication was provided to parti-
cipating centers. All patients were treated according to
the standard of care at the participating center. Data
were collected between April 2006 and September 2007
across 23 sites in 11 countries including Australia, Bel-
gium, Brazil, Germany, Greece, Jordan, Korea, Russia,
Singapore, Slovenia, and Taiwan.
Response was assessed by the investigators at the end
of caspofungin therapy (EOCT) using standard defini-
tions [11]. A complete or partial response at EOCT
was considered a favorable response; stable disease,
failure (progression of disease), or death from any
cause was considered an unfavorable response. Com-
plete response required resolution of all attributable
clinical signs and symptoms and complete resolution
of radiographic or bronchoscopic abnormalities. Partial
response required clinically meaningful improvement
in all attributable clinical signs and symptoms, a signif-
icant improvement of radiographic (at least 50%) or
bronchoscopic abnormalities, and included persistence
of radiographic sequelae regardless of the overall level
of clinical or radiographic improvement. Stable disease
included no improvement of attributable clinical signs
or symptoms and no improvement of radiographic or
bronchoscopic abnormalities. Failure included dete-
rioration in attributable clinical or radiographic
abnormalities that necessitated alternative antifungal
therapy or resulted in death.
The safety evaluations required all investigators to
report serious and non-serious clinical or laboratory
adverse event that was related to the administration of
caspofungin. Serious adverse events were those resulting
in death or incapacity, were life-threatening, required
initial or prolonged hospitalization, and included birth
defects, cancer, and those deemed to be serious by
medical judgment. An independent expert review panel
consisting of two experts (Dr. J. Maertens and Prof.
C. Viscoli) reviewed the analysis of the data for accuracy
and completeness.
Statistical Analysis
Patient demographics and baseline patient characteris-
tics were summarized. Patients were categorized
according to whether they received caspofungin as
monotherapy or whether azoles or polyenes were admi-
nistered in combination with caspofungin. Summary
statistics stratified by monotherapy and combination
therapy were also provided for first-line versus second-
line use of caspofungin. Caspofungin effectiveness and
safety were assessed by the number and percentage of
patients with a favorable response at the EOCT and
adverse event reports; 95% confidence intervals were
calculated for effectiveness data. Effectiveness was also
evaluated for various patient sub-groups including pro-
ven vs probable disease; caspofungin monotherapy vs
combination therapy; caspofungin as first-line therapy vs
salvage therapy; neutropenic status at caspofungin initia-
tion (<500 cells/μLv s≥ 500 cells/μL); and risk factors at
baseline. Additional summary statistics were provided
for length of hospital stay (LOS), survival at 7 days after
EOCT, and microbiology.
Results
A total of 103 patients with proven (n = 31; 30.1%) or
probable (n = 72; 69.9%) IA was enrolled in the registry.
The mean age of the population was 50.4 years and the
male-to-female ratio was 2:1 (Table 1). Two patients
(2%) were excluded from the effectiveness analysis
because they were still on study therapy at the time the
database was closed and therefore were not assessed.
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infection, accounting for 84.5% of cases (n = 87), fol-
lowed by blood infection (fungemia) (7.8%, n = 8).
Other sites of infection included bone/joint, sinus, liver/
spleen, external ear and trachea (one case each). Three
patients had disseminated infection (2.9%). The main
predisposing conditions included malignancy (76.7%)
and allogeneic HSCT (22.3%), followed by solid organ
transplantation (8.7%), autologous HSCT (4.9%), and
HIV/AIDS (2.9%). Many patients presented with multi-
ple predisposing factors with a mean number of 5.3
(SD= 1.78) risk factors present per patient; 57% of
patients were neutropenic (ANC<500 cells/μL) at the
start of caspofungin treatment.
Table 1 Patient demographics and baseline characteristics
Variable Monotherapy
(N = 85)
Combination therapy
(N = 18)
Overall
(N = 103)
Gender, n (%)
Male 55 (64.7%) 11 (61.1%) 66 (64.1%)
Female 30 (35.3%) 7 (38.9%) 37 (35.9%)
Mean age (years) (mean ± SD
a) 49.8 ± 15.94 53.4 ± 16.94 50.4 ± 16.09
Race, n (%)
White 49 (57.6%) 15 (83.3%) 64 (62.1%)
Asian 36 (42.4%) 3 (16.7%) 39 (37.9%)
Country, n (%)
Germany 36 (42.4%) 6 (33.3%) 42 (40.8%)
Korea 28 (32.9%) 3 (16.7%) 31 (30.1%)
Russia 8 (9.4%) 0 8 (7.8%)
Taiwan 6 (7.1%) 0 6 (5.8%)
Greece 0 5 (27.8%) 5 (4.8%)
Other 7 (8.2%) 4 (22.2%) 11 (10.7%)
Mean APACHE II score (mean ± SD) 18.3 ± 8.26 (n = 11) 18.3 ± 2.52 (n = 3) 18.3 ± 7.31 (n = 14)
SOFA score (mean ± SD) 8.8 ± 4.66 (n = 5) 0 8.8 ± 4.66 (n = 5)
Site of Infection, n (%)
Blood 8 (9.4%) 0 8 (7.8%)
Lung 72 (84.7%) 15 (83.3%) 87 (84.5%)
Bone/joint 1 (1.2%) 0 1 (1.0%)
Sinus 0 1 (5.6%) 1 (1.0%)
Liver/spleen 0 1 (5.6%) 1 (1.0%)
Other 2 (2.4%) 0 2 (1.9%)
Multiple 2 (2.4%) 1 (5.6%) 3 (2.9%)
Neutropenic at time of initiation of
caspofungin treatment, n (%)
<500 cells/μL 53 (62.4%) 6 (33.3%) 59 (57.3%)
>500 cells/μL 32 (37.6%) 12 (66.7%) 44 (42.7%)
Number of risk factors per patient
(mean ± SD)
5.4 ± 1.76 4.8 ± 1.86 5.3 ± 1.78
Risk factors and underlying medical conditions
b, n (%)
Active malignancy 70 (82.4%) 9 (50%) 79 (76.7%)
Immunosuppressive medication 64 (75.3%) 12 (66.7%) 76 (73.8%)
Neutropenia at time of hospitalization 59 (69.4%) 7 (38.9%) 66 (64.1%)
Allogeneic HSCT 18 (21.2%) 5 (27.8%) 23 (22.3%)
Prior fungal colonization 16 (18.8%) 2 (11.1%) 18 (17.5%)
Diabetes mellitus 11 (12.9%) 4 (22.2%) 15 (14.6%)
Organ transplantation 5 (5.9%) 4 (22.2%) 9 (8.7%)
Autologous HSCT 5 (5.9%) 0 5 (4.9%)
AIDS/HIV infection 3 (3.5%) 0 3 (2.9%)
aSD = standard deviation
bFrequencies of different risk factors and underlying medical conditions are not mutually exclusive.
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21.4 days (range 1-40.3 days). The mean daily dose of
caspofungin was 49.3 ± 6.97 mg. In 42 patients, no
attempt was made to have a culture-based diagnosis. Of
the 61 patients in which culture examination was per-
formed, 34 tested negative, although these patients were
identified as having proven/probable IA by the investiga-
tor, according to the other criteria (such as positive
histopathological evidence), as defined in the EORTC/
MSG guidelines. In culture-positive cases (n = 27,
26.2%), Aspergillus fumigatus was the most frequently
isolated species (n = 10), followed by A. flavus (n = 3); 9
cases yielded a positive culture for Aspergillus but did
not have the species identified. Supportive microbiologi-
cal data were missing in 5 cases; diagnosis in these cases
was based on the investigator’sj u d g m e n t .T h em a j o r i t y
of patients received caspofungin as salvage therapy
(83/103 = 80.6%) (Table 2). Seventy of these patients
received monotherapy and 13 patients received caspo-
fungin-containing combination treatment (usually with
voriconazole). The main reasons for switching to salvage
therapy included clinical failure of the first-line therapy
(69%), microbiological documentation of persistence of
the infection (8.4%), or toxicity associated with the first-
line therapy (10.8%). Antifungals administered prior to
switching to caspofungin were amphotericin B deoxy-
cholate (30.1%), fluconazole (29.1%), itraconazole
(18.4%), voriconazole (12.6%) or a lipid-based formula-
tion of amphotericin B (11.7%). Twenty patients (19.4%)
received caspofungin as first-line monotherapy (n = 15)
or combination therapy (n = 5).
Response at EOCT
An overall favorable response rate of 56.4% (57/101) was
observed in this study population. Patients receiving cas-
pofungin monotherapy and combination therapy had
response rates of 56.3% (9/16) and 56.5% (48/85),
respectively (Table 3). Those receiving first-line therapy
had a slightly higher response rate (60.0%) than those
receiving salvage therapy (55.6%). Caspofungin first-line
monotherapy was associated with a 60.0% (9/15) favor-
able response. Favorable response rates in clinically
Table 2 Patients receiving caspofungin treatment
Indication for IV caspofungin therapy Monotherapy
(N= 85) n (%)
Combination
therapy
(N = 18) n (%)
Overall
(N = 103) n (%)
Caspofungin first-line therapy 15 (17.6) 5 (27.8) 20 (19.4)
Caspofungin salvage therapy 70 (82.4) 13 (72.2) 83 (80.6)
Clinical refractory to first-line antifungal 48 (68.6) 10 (76.9) 58 (69.0)
Microbiological refractory to first-line antifungal 6 (8.6) 1 (7.7) 7 (8.4)
Toxicity
￿ Nephrotoxicity to first-line antifungal 2 (2.9) 1 (7.7) 3 (3.6)
￿ Other toxicity 6 (8.6) 0 6 (7.2)
Other* 7 (10.0) 1 (7.7) 8 (9.6)
Not reported 1(1.4) 0 1 (1.2)
*Other reasons include: Severe disease requiring combination therapy, prophylaxis, elevated Aspergillus antigen, empirical therapy, elevated creatinine
Table 3 Favorable response (complete plus partial) by
patient subgroup (N = 101)
Variable Favorable response
% (n/N) [95%CI]
Overall 56.4 (57/101) [46.7; 66.1]
Probable aspergillosis 56.3 (40/71) [44.0; 68.1]
Proven aspergillosis 56.7 (17/30) [37.4; 74.5]
Combination therapy 56.3 (9/16) [29.9; 80.2]
First line 60.0 (3/5) [14.6; 94.7]
Second Line 54.6 (6/11) [23.4; 83.3]
Monotherapy 56.5 (48/85) [45.3; 67.2]
First line 60.0 (9/15) [32.3; 83.7]
Second Line 55.7 (39/70) [43.3; 67.6]
First-line therapy 60.0 (12/20) [36.1; 80.9]
Salvage therapy 55.6 (45/81) [44.1; 66.6]
Culture examination performed 62.3 (38/61) [50.1; 74.5]
Positive 55.6 (15/27) [36.9; 76.6]
Negative 67.6 (23/34) [49.5; 82.6]
Neutropenic status at start of caspofungin
therapy
ANC < 500 cells/μL 52.5 (31/59) [39.1; 65.7]
ANC > = 500 cells/μL 61.9 (26/42) [45.6; 76.4]
Risk factors
Active malignancy 51.9 (41/79) [40.4; 63.3]
AIDS/HIV infection 66.7 (2/3) [9.4; 99.2]
Bone marrow/stem cell transplantation 53.6 (15/28) [33.9; 72.5]
￿ Autologous HSCT 40.0 (2/5) [5.3; 85.3]
￿ Allogeneic HSCT 56.5 (13/23) [34.5; 76.8]
Diabetes mellitus 57.1 (8/14) [28.9; 82.3]
Immunosuppressive medication 60.8 (45/74) [48.8; 72.0]
Neutropenia at the time of
hospitalization
53.0 (35/66) [40.3; 65.4]
Prior fungal colonization 61.1 (11/18) [35.7; 82.7]
Organ transplantation 75.0 (6/8) [34.9; 96.8]
Response evaluated in N = 101 patients.
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patients with active malignancy, 56.5% in those with
allogeneic HSCT and 53.0% in patients with neutropenia
(Table 3).
Outcomes
The overall LOS was 59.9 days. Increased LOS due to
adverse events was observed in 1 patient (1.0%), and
increased LOS due to treatment failure with caspofungin
was observed in 7 patients (6.8%). Survival rates of
74.1% (63/85) were observed at 7 days after the end of
caspofungin monotherapy and 62.5% (10/16) at 7 days
after the end of combination therapy.
Safety
No patient discontinued caspofungin therapy due to drug
interactions between caspofungin and other antifungal
drug. According to the investigator, 3/103 patients (2.9%)
experienced a serious drug-related clinical adverse event
(bronchopneumonia, respiratory failure, skin reaction),
including two patients (1.9%) who discontinued caspo-
fungin therapy (Table 4). One patient (1.0%) developed a
serious laboratory adverse event (hyperbilirubinemia)
that resulted in discontinuation of caspofungin therapy.
Twenty-three patients (27.1%) in the monotherapy and 5
patients (27.8%) in the combination therapy group died.
No reports were received from investigators attributing
any death to caspofungin therapy.
Discussion
Caspofungin regimens provided high favorable response
and survival rates in this observational registry docu-
menting real world findings. An overall favorable
response rate of 56.3% was observed in patients with
proven or probable aspergillosis treated with caspofun-
gin monotherapy or combination therapy. A total of 20/
101 patients received caspofungin as first-line therapy
(as part of a combination regimen in 5 patients), which
was associated with a 60.0% favorable response. Favor-
able responses >50% were seen in high risk patient sub-
groups, including those with a malignancy (51.9%), with
allogeneic HSCT (56.5%) or neutropenia at the time of
hospitalization (53.0%). There was a 73% survival at 7
days after EOCT. A low rate of drug-related serious
adverse events and drug-related adverse events leading
to discontinuation was observed, with no differences
noted between the safety profiles of caspofungin mono-
therapy and combination therapy.
T h eh i g hr a t e so ff a v o r a b l er e s p o n s eo b s e r v e di nt h i s
registry were impressive considering the severity of ill-
ness in the patient population. The majority of patients
in this study (81.6%) required salvage therapy due to
prior treatment failure or toxicity. The patients included
in this registry were very ill at baseline, as evidenced by
the high proportion of patients with neutropenia (57.3%)
and active malignancies (76.7%). Additionally, some
patients received caspofungin after failing amphotericin
B therapy due to lack of efficacy or intolerance. There-
fore, it should be considered that long-term persistence
of relevant amphotericin B concentration in organ tissue
may have led to effectiveness not solely attributable to
caspofungin. It is also worth noting that survival was
lower for patients who received combination therapy as
this group was likely composed of a sicker population
with a greater disease burden in comparison to those
selected for monotherapy.
The favorable effectiveness and survival results pre-
sented in this registry were consistent with the cumula-
tive published literature on caspofungin. The registry
data confirm the previously reported efficacy of caspo-
fungin monotherapy [6] and combination therapy [7] in
clinical trials. The favorable response rates and survival
rates in our study reflected trends observed with liposo-
mal amphotericin B and voriconazole when used as
first-line therapy, although there was a difference in the
time to follow up between this and the published studies
[4]. The median duration of therapy was also shorter in
this study than in clinical studies of caspofungin therapy
(median, 25 days, range, 1-196 days; median, 28 days;
range, 1-162 days) [6,7]. In a double-blind trial of
patients (n = 201) with invasive mold infections, 97% of
whom had IA, 50% of patients achieved a favorable
response with liposomal amphotericin B and 72% sur-
vived to at least 12 weeks [5]. A randomized, unblinded
study of patients (n = 144) with IA found that 52.8% of
patients who received voriconazole had a favorable
Table 4 Adverse events
Type of Adverse Events Clinical Adverse Events*
N = 103
n (%)
Laboratory Adverse Events**
N = 103
n (%)
Any adverse events 4 (3.9) 8 (7.8)
Serious adverse events 3 (2.9) 1 (0.9)
Serious adverse events leading to discontinuation 2 (1.9) 1 (0.9)
* Clinical adverse events include: bronchopneumonia; skin reaction; respiratory failure; and abdominal pain
**Laboratory adverse events include: increase in aspartate aminotransferase, alanine aminotransferase, blood alkaline phosphatase, blood bilirubin, gamma
glutamyltransferase; leukopenia; hyperbilirubinemia; and hypokalemia.
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amphotericin B; 12-week survival rates of 70.8% and
57.9% were achieved in the voriconazole and amphoteri-
cin B groups, respectively [4]. A prospective database
study of 85 patients with allogeneic HSCT, 24 with graft
versus host disease, found an overall response rate of
31% with amphotericin B lipid complex as first- or
second-line therapy [12].
The present registry had several inherent limitations.
As an observational registry documenting real world use
of caspofungin in proven and probable IA, no compara-
tor arm was available and no superiority or non-inferior-
ity could be determined. In addition, the low numbers
of patients in some of the categories may have skewed
the results. While deaths occurring during the observa-
tion period were determined to be unrelated to caspo-
fungin, the reasons for death were not collected with
the study data. Diagnosis of proven and probable IA
was based on investigators’ clinical judgment and local
practice standards using the EORTC/MSG criteria as a
guide. All sites were not mandated to provide compre-
hensive diagnostic information and treatment practices
for IA, which may have varied between countries and
regions. This could have resulted in misclassification of
disease. Cases with changes highly suggestive of IA on
r a d i o l o g yw e r ee l i g i b l ef o rs t u d yi n c l u s i o na sp r o b a b l e
IA, whereas EORTC/MSG criteria would categorize
these cases as possible IA. Therefore, possible cases
could have been included as probable cases resulting in
a bias away from null and hence, an overestimation of
response rates. As an observational study, reports of
fungemia were accepted as recorded by investigators
and all patients with proven or probable IA were
included. Many patients with A. fungemia have a low
performance score and exhibit co-morbidities which
excludes them from clinical studies, but not from regis-
tries; therefore, the number of fungemia cases in our
study may have been greatert h a ne x p e c t e d .F i n a l l y ,
there was a limited follow-up period after caspofungin
therapy ended.
Conclusions
In this observational registry of daily clinical practice,
antifungal regimens in which caspofungin was used as
monotherapy or combination therapy, and as either
first-line or second-line therapy, provided effective treat-
ment in severely ill patients with proven or probable IA.
Caspofungin was both effective and well tolerated
among high-risk patient groups such as those with neu-
tropenia and active malignancies.
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